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Abstract
Elderly patients are a special category of patients in whom poly-morbid pathology is often observed. 
Combination of cardio-vascular diseases and community-acquired pneumonia (CAP) is the most 
prevalent condition, occurring in patients aged over 60 years. Such comorbidity is associated with 
difficulties not only at the stage of diagnosing, but also in administering therapy, taking into account the 
necessity of simultaneous administering both of anti-bacterial therapy and that of cardio-vascular 
pathology diseases, physiologic changes of an elderly organism and complicated inter-drug interactions. 
Keywords: pneumonia, elderly patient, cardio-vascular pathology, comorbidity, drug interaction, anti-
bacterial therapy. 
1. Introduction
Progressing aging of the population is one of the most topical problems of the present time. 
Today there are about 650 million of elderly persons in the world [7]. In this category of 
patients pneumonias acquire specific significance. The annual incidence of pneumonia 
increases together with the age: from 1-11, 6 of cases per thousands of young and middle aged 
people to 20-44 persons per 1000 in elderly [23, 36]. Community-acquired pneumonia (CAP) is 
one of the most frequent reasons, which requires hospitalization to therapeutic unit. Lethality 
in CAP in persons without concomitant diseases ranges about 1-3%, while in elderly patients 
groups with background comorbidities it achieves 30%. In the same time mortality of CAP in 
elderly patients occupy the 1-st place in the structure of mortality from infectious diseases and 
being on the4-th in elderly persons, leaving IHD, strokes and malignant neoplasms behind it [6, 
15].  
It is well-known, that elderly patients usually suffer from poly-morbid pathology. In 80-90% 
of elderly patients the most often revealed cardio-vascular diseases (CVD) are: arterial 
hypertension, ischemic heart disease, multi-focal atherosclerosis as well as diabetes mellitus, 
which require permanent therapy.  
In the present work peculiarities of etiology, pathogenesis, clinical manifestations and 
treatment of CAP in elderly patients are discussed.  
2. Etiology
In a whole, bacterial pathogens that cause CAP in elderly aged groups does not differ from that 
of in patients of young and middle age. Up to today S. pneumoniae (30-50% of cases) remains 
the single most common organism identified in hospitalized elderly patients with CAP [5, 6]. 
CAP caused by Gram-negative bacteria are often related to comorbid illnesses, thus elderly 
patients are more likely to succumb to these organisms (H. Influenzae (tо 20%), E. coli, 
Рoteusspp Kl. Рneumonia) [6, 15]. In elderly patients, hospitalized because of CAP, may be 
revealed combined, so called co-infection, nonetheless such bacterial pathogens as 
Mycoplasma pneumoniae, Chlamydia pneumoniae (up to 5%) are revealed much rare than in 
young patients [27]. A higher risk of aspiration in elderly and senile age patients and pulmonary 
circulation congestion, results to increasing of the role of oropharyngeal flora in this category 
of patients. 
3. Pathogenesis
There are a number of peculiarities about pneumonia development in elderly patients, linked 
first of all with age-related anatomic and functional changes of pulmonary tissue and cardio-
vascular system, known as a conception of a “senile lung”. Main pathogenetic factors 
contributing to development of inflammatory process in the lung are [5, 6, 8, 25, 40]:  
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- decrease of the number of elastic fibers in the pulmonary 
tissues; 
- decrease of anti-oxidant defense and enforcement of 
peroxide oxidation; 
- reduction of alveolar-capillary surface, which causes 
decrease of diffusion ability of the lungs with 
development of arterial hypoxemia; 
- decrease of surfactant activity, phagocytic activity of 
alveolar macrophages and neutrophils; 
- decrease of mucociliary clearance. 
At the same time age-related depression of cough reflex, 
caused by reduction in sensitivity of bronchial mucous 
membrane, leads to disturbance of trachea-bronchial tree 
clearing and aggravates disturbance of pulmonary ventilation. 
Mentioned factors contribute to increase of microbe 
colonization of mucous membrane of the respiratory tract and 
development of broncho-pulmonary infection development. 
Suppression of immune response at the respiratory tract, 
caused by disorder of drainage function of the lungs and 
activation of microbe microflora in the presence of 
background pathology leads to slow resolution of 
inflammatory process. Decrease of cardiac output in elderly 
people leads to a chronic decrease of arterial blood 
oxygenation. Age-related changes of arterial vessels (sclerotic 
induration of intima, decrease of aorta and pulmonary artery 
elasticity) cause the defection in dilatation and contraction 
which lead to decrease of adaptation abilities both in systemic 
and pulmonary circulation [10].  
Mentioned changes lead to depression of respiratory center 
response and peripheral chemoreceptors to hypoxia and 
hypercapnia, thus changing the exercise tolerance. It is 
important to remember, that pneumonia also develops, when 
virulence of pathogen exceeds the ability of immune response. 
Such situation may occur against the background of 
insufficient immune response caused by concomitant diseases, 
such as diabetes mellitus, congestive heart failure.  
4. Peculiarities of CAP’s clinical presentation in elderly
people  
Late diagnostics of pneumonias is one of the causes of a high 
lethality. Namely, in the group of patients over 60 years old 
the frequency of CAP misdiagnosis at pre-hospitalization stage 
is two times higher than in other age-related groups. So, 
hypodiagnostics of pulmonary diseases occupies one of the 
leading places among other pathologies and makes up 11,76%. 
The main role of misdiagnosis (up to 86%) possess subjective 
factors, such as imperfect examination of a patient, incorrect 
rendering of clinical findings [4, 5, 34]. While observing such 
patients one should always remember that on one side such a 
patient most commonly has clinical features of pneumonia, 
and on the other side – suffers at the same time from two 
diseases as minimum (comorbidity!). That is why there are 
several important directions in front of internist, dealing with 
an elderly patient with a suspected CAP. First of all, it is a 
confirmation of diagnosis and an adequate evaluation of 
pneumonia severity for defining indications to treatment in 
conditions of resuscitation and intensive therapy unit and for 
administering adequate therapy. Contrariwise, it is necessary 
to reveal concomitant CVD, as such diseases in the 
decompensation stage may be mistakenly taken for pathology 
of broncho-pulmonary system or aggravate pneumonia course. 
CAP diagnosis is considered to be established in 
roentgenologically confirmed infiltration of pulmonary tissue 
and presence of at least 2 clinical signs: acute disease onset 
with body temperature higher than 38 0С, physical signs 
(deadened or dull percussion sound, diminished or rough 
bronchial breath sounds, focus of ringing fine moist rales 
and/or crepitation), leukocytosis of more than 10 х109/l and/or 
stab neutrophils shift of more than 10%. 
One of the important peculiarities of CAP’s clinical symptoms 
in elderly patients is the absence of acute onset or slightly 
marked temperature reaction. Only in 75-80% of elderly and 
senile age patients with pneumonia fever is observed [20, 31, 36]. 
The disease course, compared with younger patients, is often 
characterized by normal or even decreased temperature, which 
is prognostically less favourable. Leukocytosis which is 
characteristic for pneumonia may be absent in one third of 
patients, being also unfavorable prognosis sign, especially in 
presence of neutrophil shift. Such classical signs as dullness of 
percussion sound and crepitating may be not defined due to 
dehydration of tissues caused by diuretics taking; fine moist 
rales may be the consequence of pulmonary edema 
developing, dry rales – of pneumo-sclerosis manifestation. 
Diagnostic value of such a symptom as cough in elderly 
patients may be underestimated due to depression of cough 
reflex in patients with the anamnesis of stroke. Breathlessness 
in elderly patients with CAP may be linked with the presence 
of obesity, decompensation of heart failure and anemia. 
Exacerbation and decompensation of concomitant diseases 
(aggravation or appearance of heart failure signs, heart rhythm 
disorders, decompensation of diabetes mellitus, signs of 
respiratory insufficiency, various neurologic symptomatic) 
may come to the fore in elderly patients with CAP.  
False rendering of clinical data may be the cause of hyper- or 
hypodiagnostics of pneumonia of elderly patients and thus 
inadequate management strategy. Data presented above reflect 
complexity of CAP diagnostics in elderly patients with 
concomitant cardiac pathology.  
Chest X-ray examination in frontal anterior and lateral 
projections is the optimal method of diagnostics, which makes 
it possible to confirm or rule out pneumonia or its 
complications as well as to assess dynamics of the chosen 
treatment. X-ray picture of CAP does not have interrelation 
with pneumonia etiology, severity of disease course and 
doesn’t give the opportunity to give diseases prognosis [26].  
To evaluate degree of pneumonia severity, risk of lethal 
outcome and adequate choice of management strategy of 
patients with CAP, score scale PORT, CURB- 65, SMRT-CО 
are used. Application of prognostic scales gives a great help 
for the physician in choosing adequate management strategy 
for patients with CAP. One of the most accessible score scale 
for practical work is simplified scale CRB – 65, without 
considering the urea level findings, which gives the possibility 
for general practitioners already at pre-hospitalization stage to 
define clinical group of pneumonia and decide where to treat 
patient [26, 28, 29, 30]. 
According to clinical observations data, pulse-oximetry is 
accessible and simple screening method in patients with CAP. 
Decrease in arterial oxygen saturation (SaO2 <90%) is an 
important criterion, making it possible to specify indications 
for patient’s hospitalization, despite absence of obvious signs 
of CAP and hypoxemia [31, 38]. 
5. Treatment
Antibacterial therapy is an initial and defining step in CAP 
treatment. Principles of antibacterial therapy management are 
stated in appropriate international and national clinical 
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protocols [12, 24, 35, 37, 41, 43, 44]. In the presented work discussing 
not even the details of the proper and adequate choice of 
medicine, but peculiarities of anti-bacterial therapy, when it is 
necessary to prolong taking cardiologic medicines.  
Principles of antibiotics administration:  
- wide spectrum of drug action, considering poly-etiologic 
character of pneumonia in persons over 60;  
- timely initiation of antibacterial therapy (first 4 hours after 
established diagnosis); 
- proved clinical effectiveness; 
- adequacy of dosing, route of taking and term of usage; 
- awareness about presence of resistance to antibiotics in 
the hospital unit;  
- considering pneumonia degree severity; 
- considering functional state of liver and kidneys;  
- considering possible side effects of medications and 
avoiding administering those ones which may cause side 
effects and course of the background and concomitant 
diseases;  
- decreasing risk of antagonist interaction of anti-bacterial 
agents, unwanted interactions with other medicinal agents, 
risk of allergic reactions development by means of 
administering single-drug therapy;  
- administration of medications with various routes of 
introduction using regimen of «step-by-step» therapy [14, 
16, 19, 21, 22]. 
One of the causes of inadequate clinical and bacteriological 
efficacy of antibiotics in elderly persons is changes of 
pharmacokinetics of medicinal agents, which lead to the 
change of pharmacodynamic effects [1, 13, 5]. Age-related 
decrease of the number of functioning hepatocytes, hepatic 
blood flow and correspondingly activity of microsomal 
ferments, first of all of cytochrome Р-450, leads to retardation 
of inactivation and elimination of medicinal agents in the liver 
and growth of antibiotics concentration, metabolized by the 
liver [24]. A lot of medical remedies, used in cardiologic 
practice, subjected to oxidations which undergo bio-
transformation with the involvement of this enzyme system. 
Specifically, klopidogrel, calcium channels blockers, 
amiodaron, varfarin, sildenafil, statins, as well as some 
antibiotics of wide spectrum of action are metabolized with the 
involvement of the same isoenzymes of cytochrome Р450 
(CYP2C9, CYP2C19, CYP3A4) [3] .  
 In such a way, simultaneous taking of verapamil, 
erythromycin and statins can lead to increase their 
concentration in the blood up to 3 times [2, 3, 11]. It is important 
to remember, that if a medication has a low bioavailability 
when taken orally, then simultaneous administration of 
medications being its inductors or inhibitors may substantially 
change its bioavailability. For example, inhibitors of 
isoenzyme CYP3A4, may sharply increase bioavailability of 
medicinal agent, period of its half-life, thereby to increase its 
concentration in the blood and enhance effect, what may be 
considered as an acute overdose. Statins (simvastatin, 
atorvastatin) which are characterized by low indices of 
bioavailability on the background of simultaneous taking 
inhibitors CYP3A4 (clarithromycin, erythromycin), may lead 
to the increase of their concentration in the blood, causing 
diffuse myalgia, growth of creatine phosphokinase level and 
acute renal insufficiency [2, 17]. Due to this, it is necessary ether 
diminish statin dose or usemedications which may be an 
alternative one in patients receiving inhibitors CYP3A4, e.g. 
rosuvastatin metabolized by CYP2С9. It is proved by 
population cohort investigation of Canadian scientists who 
have studied incidence of development of statins toxic effects 
in patients over 65 years of age taking these medicines for a 
prolonged period of time after combined usage with 
clarithromycin (n=72591) or erythromycin (n=3267) as 
compared with azithromycin (n=68478) [17, 39] . According to 
the published data, combined administration of statins with 
clarithromycin or erythromycin led to increase of risk of 
hospitalization in connection of rabdomyolis, comparing with 
azithromycin taking only. Increase of absolute risk made up 
0,02% and relative risk made up 2,17. Risk of development of 
acute renal lesion and overall mortality to all causes increases 
as well – increase of absolute risk being 1, 26% and 0,25% 
respectively. On the other side, risk of similar interaction is 
much less in medications with a high bioavailability, as even 
in usual conditions their concentration in the blood is close to 
maximal. Only intravenous administration of medicinal agent 
provides 100% bioavailability. 
Decrease of glomerular filtration rate (GFR) in persons over 
60 years has also a great importance. As consequence, 
excretion of many medicinal agents is slowed down in elderly 
patients, which leads to the growth of their concentration in the 
blood [32]. Thus, administration of antibacterial agents with 
kidney elimination pathway require a careful dose correction 
in elderly patients with renal dysfunction, according to GFR. 
For example, such «respiratory» fluoroquinolone as 
levofloxacin should be administered with caution to the 
patients with creatinine clearance< 50 ml/min, as its half-life 
period increases by 4–5 times on the background of such renal 
dysfunction. Protected amoxicillin requires dose correction in 
creatinine clearance< 30 ml/min. At the same time, another 
fluoroquinolone – moxifloxacinis excreted predominantly 
through the digestive tract and its dose regimen in patients 
with renal insufficiency does not change. Administration of 
such medications as azithromycin and ceftriaxone does not 
depend on creatinine clearance too [42]. Sometimes, in case of 
marked edemas (in case of cardio-vascular decompensation), a 
standard therapeutic or a little bit raised initial dose may be 
required, which will make it possible to overcome excessive 
re-distribution of medication in organism’s tissues and achieve 
bactericide or bacteriostatic concentration in the blood and 
tissues.  
It is also necessary to bear in mind that CAP treatment in 
elderly persons with concomitant cardiac pathology is linked 
with additional difficulties. The main reason of it is the 
necessity of persons over 60 of receiving basic therapy of 
concomitant diseases. The largest number of inter-drug 
interactions is observed during simultaneous taking of 
antibiotics and cardio-vascular medications. Taking of anti-
bacterial medications together with anti-coagulants, 
thrombolytics, inhibitors of thrombocytes aggregation may 
lead to increase of bleeding risk. Macrolides may increase 
plasma concentration of statins (increase of rabdomyolis) and 
digoxin (glycoside intoxication).Mutual taking of 
fluoroquinolones (levofloxacin, moxifloxacin) and anti-
arrhythmic medications may cause lengthening of QT interval 
– the risk of development of such ventricular arrhythmia as
“torsade de pointes”.  
However, despite the fact that poly therapy may lead to 
increase of side effects incidence, it is often impossible to 
discontinueofanti-aggregant, anti-arrhythmic, anti-
hypertensive and some other drugs taking, as it is entailed with 
great risk of complications development and lethal outcomes 
because of concomitant disease. Administration of only 
necessary medications possessing the highest efficacy and the 
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least number of side effects is, therefore, the main criterion of 
drug therapy. Polyprogmasy should be assessed as a specific 
feature of elderly person’s treatment, which requires a more 
thorough and accurate physician’s control (ECG, INR, ALT, 
AST, creatinine, electrolytes, GFR calculation).  
One of the most important ways of CAP prevention in elderly 
persons with concomitant cardiac pathology is vaccination 
with pneumococci and influenza vaccines. Despite the fact that 
such means of prevention in elderly people is considered to be 
moderately effective, this makes it possible to decrease 
incidence of upper respiratory tract infections, pneumonia, 
decompensation of CVD [33].  
6. Conclusion
Elderly patients practically always suffer from polymorbid 
pathology. CAP most often develops on the background of 
cardio-vascular diseases, which require continuous therapy of 
this comorbidity. Mutual influence of diseases, involutive 
processes of natural aging, action of drug therapy change 
clinical picture and course of the disease, character and 
severity of complications, limit or complicate treatment-
diagnostic search. Application of pneumonia severity scales 
CRB-65 and routine determination of SaO2 can make it 
possible to define clinical group of pneumonia patients and 
administer adequate therapy. In order to make treatment of 
elderly and seniors as much safe as possible, one should 
always remember about possible ways of medicine’s side 
effects prevention. For example, when it is necessary to 
administer antibiotics with liver elimination pathway and 
involvement of isoenzyme cytochromeР450 (CYP3A4) to the 
patients receiving statins, one should temporally stop taking 
statins during of antibacterial therapy, to control unwanted 
medications interactions phenomena or use alternative 
antibacterial medications which do not interact with statins 
(azithromycin, fluoroquinolones, cephalosporins, penicillins).It 
is obligatory to evaluate a renal function (calculation of GFR) 
in elderly patients for defining optimal individual dose of 
antibiotics or taking medications with another elimination 
pathway in case of significant renal insufficiency. In the 
majority of elderly patients with CAP on the background of 
cardio-vascular diseases, treatment of CVD does not stop and 
inter-drug interactions must be taken into account. Polytherapy 
is, nevertheless, one of the most optimal treatment strategies of 
elderly patients. 
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